This Fall Will Be a Vaccination Reboot
In one sense, this is how it was always supposed to go: When viruses evolve, vaccines should follow, and sometimes try to leap ahead. The COVID-19 shots that the U.S. has used to inoculate hundreds of millions of people are simply so new that they’ve never had to undergo a metamorphosis; up until now, their original-recipe ingredients have stood up to SARS-CoV-2 well enough. But the virus they fight has changed quite radically, and this fall, the vaccines will finally, finally follow suit.
Today, an advisory committee to the FDA recommended that our current slate of shots be updated to include a piece of an Omicron subvariant, with the aim of better tailoring the vaccine to the coronavirus variants that could trouble us this fall. Neither the agency nor its outside expert panel has yet reached consensus on which version of Omicron will be the best choice, and whether the next round of shots will still contain the original version of the virus as well. Regardless, a new formulation with any bit of Omicron will constitute a bet that these ingredients will better protect people than another dose of the original vaccine recipe, whose protective powers have been fading for many months.
[Read: The U.S. is about to make a big gamble on our next COVID winter]
The virus’s own mutational hijinks will determine, in part, how
You’re reading a preview, subscribe to read more.
Start your free 30 days